Medpace PE ratio MEDP

Share price divided by earnings per share over the last twelve months, since 2017.

Today, Oct 23, 2026: 39.2×
9-year median: 34.5×
Against its 9-year history: 69th; percentile: 0 is its lowest day, 100 its highest
9-year range: 22.5× to 63.0×
Peer median: 42.1×

Medpace's PE ratio is 39.2× as of Oct 23, 2026: a share price of $669.20 against $17.05 of earnings per share over the last twelve months.

That is above its 9-year median of 34.5×, higher than on 69% of days in the last 9 years.

Over that time it ranged from 22.5× in May 2025 to 63.0× in Oct 2017.

The median for 10 diagnostics and research stocks of a similar size is 42.1×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	39.2×	25.8×	42.7×
2025	39.7×	22.5×	42.3×
2024	29.9×	27.2×	46.0×
2023	35.9×	24.0×	36.5×
2022	32.6×	24.9×	38.9×
2021	45.1×	38.0×	51.5×
2020	42.6×	25.2×	45.5×
2019	33.7×	25.8×	42.1×
2018	31.0×	28.3×	56.8×
2017	53.3×	47.7×	63.0×

Against its peers

Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.

Company	PE ratio
MEDPMedpace	39.2×
RVTYRevvity	75.6×
LHLabcorp	27.2×
DGXQuest Diagnostics	25.7×
MTDMettler-Toledo International	37.6×
BIOBio-Rad Laboratories	44.8×
CAICaris Life Sciences	86.5×
ILMNIllumina	50.1×
IDXXIDEXX Laboratories	39.4×
WATWaters	113×
IQVIQVIA	34.7×
Peer median	42.1×

Where Medpace ranks

#10of 20Diagnostics and research stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Medpace

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.